This Viewpoint discusses whether the changes in the health care marketplace, the evolution of precision medicine, and the uniqueness of drug development and labeling for cancer diagnoses make the Orphan Drug Act less necessary and less relevant today than at its inception.
https://ift.tt/2MLeB2B
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου